Heron Therapeutics, Inc. (LON:0J4V)

Market Cap	157.24M -28.6%
Revenue (ttm)	115.38M +12.6%
Net Income	-10.10M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,641
Average Volume	20,174
Open	1.150
Previous Close	1.200
Day's Range	1.119 - 1.150
52-Week Range	1.000 - 2.660
Beta	1.25
RSI	38.51
Earnings Date	Feb 27, 2026

About Heron Therapeutics

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 122
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J4V

Financial Performance

In 2024, Heron Therapeutics's revenue was $144.29 million, an increase of 13.57% compared to the previous year's $127.04 million. Losses were -$13.58 million, -87.72% less than in 2023.

Financial numbers in USD